Will Moderna Soar on Nov. 6?

Investors are excited about Moderna's personalized cancer vaccine candidate, which recently delivered positive clinical trial data. The stock surged after data was released in August but has given up some gains in recent days.

The Motley Fool • 16 hours ago

Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • 10 hours ago

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?

GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.

Zacks Investment Research • 6 hours ago

Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's work

Stéphane Bancel defended his melanoma data and argued that rivals can't easily copy the technology.

WSJ • Oct 28, 2026

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically.

The Motley Fool • Oct 28, 2026

Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.

24/7 Wall Street • Oct 28, 2026

Moderna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.

Moderna CEO Stéphane Bancel says the biotech's competitive edge stems from its mRNA platform, likening it to software in Big Tech.

Barrons • Oct 27, 2026

William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Run

Moderna Inc. (NASDAQ:MRNA) shares are trading lower Tuesday after William Blair downgraded the stock to Market Perform from Outperform on Monday, citing valuation concerns.

Benzinga • Oct 27, 2026

Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?

Merck & Co. NYSE: MRK and Moderna NASDAQ: MRNA just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial.

MarketBeat • Oct 27, 2026

Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine

Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.

Investors Business Daily • Oct 26, 2026